{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:05:35Z","timestamp":1768280735750,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["HHSN271201400028C\/75N95019D00013"],"award-info":[{"award-number":["HHSN271201400028C\/75N95019D00013"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["HHSN271201400028C\/75N95019D00013"],"award-info":[{"award-number":["HHSN271201400028C\/75N95019D00013"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["U10DA013714"],"award-info":[{"award-number":["U10DA013714"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA013035"],"award-info":[{"award-number":["UG1DA013035"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["U10DA013714"],"award-info":[{"award-number":["U10DA013714"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["U10DA13720"],"award-info":[{"award-number":["U10DA13720"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pragmatic primary care trials aim to test interventions in \u201creal world\u201d health care settings, but clinics willing and able to participate in trials may not be representative of typical clinics. This analysis compared patients in participating and non-participating clinics from the same health systems at baseline in the PRimary care Opioid Use Disorders treatment (PROUD) trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This observational analysis relied on secondary electronic health record and administrative claims data in 5 of 6 health systems in the PROUD trial. The sample included patients 16\u201390\u2009years at an eligible primary care visit in the 3\u2009years before randomization. Each system contributed 2 randomized PROUD trial clinics and 4 similarly sized non-trial clinics. We summarized patient characteristics in trial and non-trial clinics in the 2\u2009years before randomization (\u201cbaseline\u201d). Using mixed-effect regression models, we compared trial and non-trial clinics on a baseline measure of the primary trial outcome (clinic-level patient-years of opioid use disorder (OUD) treatment, scaled per 10,000 primary care patients seen) and a baseline measure of the secondary trial outcome (patient-level days of acute care utilization among patients with OUD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients were generally similar between the 10 trial clinics (<jats:italic>n<\/jats:italic>\u2009=\u2009248,436) and 20 non-trial clinics (<jats:italic>n<\/jats:italic>\u2009=\u2009341,130), although trial clinics\u2019 patients were slightly younger, more likely to be Hispanic\/Latinx, less likely to be white, more likely to have Medicaid\/subsidized insurance, and lived in less wealthy neighborhoods. Baseline outcomes did not differ between trial and non-trial clinics: trial clinics had 1.0 more patient-year of OUD treatment per 10,000 patients (95% CI: \u2212\u20092.9, 5.0) and a 4% higher rate of days of acute care utilization than non-trial clinics (rate ratio: 1.04; 95% CI: 0.76, 1.42).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>trial clinics and non-trial clinics were similar regarding most measured patient characteristics, and no differences were observed in baseline measures of trial primary and secondary outcomes. These findings suggest trial clinics were representative of comparably sized clinics within the same health systems. Although results do not reflect generalizability more broadly, this study illustrates an approach to assess representativeness of clinics in future pragmatic primary care trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-08915-1","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T15:05:22Z","timestamp":1672326322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Baseline representativeness of patients in clinics enrolled in the PRimary care Opioid Use Disorders treatment (PROUD) trial: comparison of trial and non-trial clinics in the same health systems"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0087-3429","authenticated-orcid":false,"given":"Paige D","family":"Wartko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxiang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abisola E.","family":"Idu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onchee","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail G.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer F.","family":"Bobb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Saxon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia I.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan M.","family":"Braciszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael P.","family":"Burganowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana E.","family":"Horigian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah K.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise M.","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine A.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"8915_CR1","doi-asserted-by":"publisher","first-page":"h2147","DOI":"10.1136\/bmj.h2147","volume":"350","author":"K Loudon","year":"2015","unstructured":"Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147.","journal-title":"BMJ"},{"key":"8915_CR2","doi-asserted-by":"publisher","first-page":"a2390","DOI":"10.1136\/bmj.a2390","volume":"337","author":"M Zwarenstein","year":"2008","unstructured":"Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. Bmj. 2008;337:a2390.","journal-title":"Bmj"},{"key":"8915_CR3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3389\/fpsyt.2018.00654","volume":"9","author":"J Lally","year":"2018","unstructured":"Lally J, Watkins R, Nash S, Shetty H, Gardner-Sood P, Smith S, et al. The representativeness of participants with severe mental illness in a psychosocial clinical trial. Front Psychiatry. 2018;9:654.","journal-title":"Front Psychiatry"},{"issue":"10","key":"8915_CR4","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamainternmed.2019.1501","volume":"179","author":"B Smyth","year":"2019","unstructured":"Smyth B, Haber A, Trongtrakul K, Hawley C, Perkovic V, Woodward M, et al. Representativeness of randomized clinical trial cohorts in end-stage kidney disease: a Meta-analysis. JAMA Intern Med. 2019;179(10):1316\u201324.","journal-title":"JAMA Intern Med"},{"key":"8915_CR5","doi-asserted-by":"publisher","first-page":"103822","DOI":"10.1016\/j.jbi.2021.103822","volume":"119","author":"JR Rogers","year":"2021","unstructured":"Rogers JR, Hripcsak G, Cheung YK, Weng C. Clinical comparison between trial participants and potentially eligible patients using electronic health record data: a generalizability assessment method. J Biomed Inform. 2021;119:103822.","journal-title":"J Biomed Inform"},{"issue":"5","key":"8915_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","volume":"171","author":"DP Alford","year":"2011","unstructured":"Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425\u201331.","journal-title":"Arch Intern Med"},{"issue":"1","key":"8915_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13722-021-00218-w","volume":"16","author":"CI Campbell","year":"2021","unstructured":"Campbell CI, Saxon AJ, Boudreau DM, Wartko PD, Bobb JF, Lee AK, et al. PRimary care opioid use disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. Addict Sci Clin Pract. 2021;16(1):9.","journal-title":"Addict Sci Clin Pract"},{"key":"8915_CR8","volume-title":"Collaborative models for medication assisted treatment: key elements of the Massachusetts collaborative care model","author":"Medicaid innovation accelerator program","year":"2019","unstructured":"Medicaid innovation accelerator program. Collaborative models for medication assisted treatment: key elements of the Massachusetts collaborative care model: Centers for Medicare & Medicaid Services; 2019.\u00a0https:\/\/www.medicaid.gov\/state-resource-center\/innovation-accelerator-program\/iap-downloads\/reducingsubstance-use-disorders\/mat-key-elements-ma.pdf."},{"key":"8915_CR9","volume-title":"General requirements for informed consent","author":"United States Department of Health and Human Services","year":"2021","unstructured":"United States Department of Health and Human Services. General requirements for informed consent: 45 Code of Federal Regulations (CFR) Subtitle A \u00a7 46.116; 2021."},{"key":"8915_CR10","volume-title":"Other requirements relating to uses and disclosures of protected health information","author":"United States Department of Health and Human Services","year":"2017","unstructured":"United States Department of Health and Human Services. Other requirements relating to uses and disclosures of protected health information: 45 Code of Federal Regulations (CFR) Subtitle A \u00a7 164.514; 2017."},{"issue":"7","key":"8915_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jama.2021.13304","volume":"326","author":"A Flanagin","year":"2021","unstructured":"Flanagin A, Frey T, Christiansen SL. Committee AMAMoS: updated guidance on the reporting of race and ethnicity in medical and science journals. Jama. 2021;326(7):621\u20137.","journal-title":"Jama"},{"issue":"12","key":"8915_CR12","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jpain.2019.05.006","volume":"20","author":"M Mayhew","year":"2019","unstructured":"Mayhew M, DeBar LL, Deyo RA, Kerns RD, Goulet JL, Brandt CA, et al. Development and assessment of a crosswalk between ICD-9-CM and ICD-10-CM to identify patients with common pain conditions. J Pain. 2019;20(12):1429\u201345.","journal-title":"J Pain"},{"issue":"1","key":"8915_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"key":"8915_CR14","volume-title":"2014\u20132018 American community survey 5-year public use microdata samples [SAS data file]","author":"US Census Bureau","year":"2022","unstructured":"US Census Bureau. 2014\u20132018 American community survey 5-year public use microdata samples [SAS data file]; 2022.\u00a0www.census.gov\/programs-surveys\/acs."},{"issue":"3","key":"8915_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivariate Behav Res"},{"issue":"4","key":"8915_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","volume":"54","author":"ST Normand","year":"2001","unstructured":"Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54(4):387\u201398.","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 1","key":"8915_CR17","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1007\/BF03375463","volume":"47","author":"M Veitenhansl","year":"2004","unstructured":"Veitenhansl M, Stegner K, Hierl FX, Dieterle C, Feldmeier H, Gutt B, et al. 40(th) EASD annual meeting of the European Association for the Study of diabetes : Munich, Germany, 5-9 September 2004. Diabetologia. 2004;47(Suppl 1):A1\u2013A464.","journal-title":"Diabetologia"},{"issue":"1","key":"8915_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/pam.21660","volume":"32","author":"RB Olsen","year":"2013","unstructured":"Olsen RB, Orr LL, Bell SH, Stuart EA. External validity in policy evaluations that choose sites purposively. J Policy Anal Manage. 2013;32(1):107\u201321.","journal-title":"J Policy Anal Manage"},{"issue":"3","key":"8915_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/1740774519833679","volume":"16","author":"SM Shortreed","year":"2019","unstructured":"Shortreed SM, Rutter CM, Cook AJ, Simon GE. Improving pragmatic clinical trial design using real-world data. Clin Trials. 2019;16(3):273\u201382.","journal-title":"Clin Trials"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08915-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T15:08:40Z","timestamp":1672326520000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08915-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8915"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08915-1","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"19 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A single Institutional Review Board (IRB), Advarra, approved the study including providing waivers of consent and HIPAA authorization, with all sites ceding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Outside the work of this study, Dr. Wartko was funded through a contract awarded to the Harvard Department of Population Medicine from GlaxoSmithKline to assess medication use in pregnancy. Dr. Wartko receives funding from a research contract awarded to Kaiser Permanente Washington Health Research Institute from Syneos Health to conduct Food and Drug Administration-mandated post-marketing research on the risks of opioid analgesic use. Dr. Boudreau receives funding from a consulting contract from Syneos Health to conduct Food and Drug Administration-mandated post-marketing research on the risks of opioid analgesic use. Dr. Boudreau is now an employee of Genentech, Inc. Ms. Yu was awarded a grant by Bayer AG. Dr. Saxon has received consulting fees from Indivior, Inc., travel support from Alkermes, PLC., and royalties from UptoDate, Inc. Dr. Campbell is supported by grants and contracts from the National Institute on Drug Abuse (UG1-DA040314, R01-DA047405) and the Food and Drug Administration. She has received support managed through her institution from the Industry PMR Consortium, a consortium of companies working together to conduct post-marketing studies required by the Food and Drug Administration that assess risks related to opioid analgesic use.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1593"}}